StockWatch
·
Q2 FY-2027 RESULTS · HESTERBIO

Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%

PAT +44% YoY · revenue +38% · margins expanding

Q2 FY27 resultsHESTERBIOHESTER BIOSCIENCES LTD.05 Nov 2026 · 3 min read
Revenue

₹97.91 Cr

+38% YoY

PAT (consolidated)

₹20.63 Cr

+44% YoY

Net margin

20.75%

+3pp YoY

EPS

₹23.94

Hester Biosciences' consolidated (primary) revenue came in at ₹97.91 Cr, up 38% YoY and 27% QoQ, with PAT of ₹20.63 Cr, up 44% YoY as reported (~41% on an adjusted basis stripping a minor ₹0.42 Cr exceptional gain this quarter — the year-ago quarter had no exceptional items, so the YoY comparison is largely clean). Standalone, the core India entity, posted revenue of ₹82.93 Cr (+28% YoY) and PAT of ₹16.66 Cr (+131% YoY). This is a micro-cap with no analyst consensus coverage located for this print, so street expectations are unknown rather than beaten or missed.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹97.91 Cr+26.8%+38%
Expenses₹75.31 Cr+16.6%+14.4%
PAT₹20.63 Cr-78.7%+44%
Net margin20.75%-79.2pp+3pp
EPS₹23.94-78.9%+42.1%

The growth was margin-led as much as volume-led: standalone gross margin rose to 78% from 68% a year ago and EBITDA margin to 35% from 21%, which management attributes to a favourable product mix and cost discipline; consolidated EBITDA margin expanded to 37% from 33%. Poultry Healthcare (standalone) grew revenue 27% YoY on institutional penetration and customer engagement, while Animal Healthcare grew 34% YoY in the quarter on tender execution — though H1 Animal Healthcare revenue is still down 14% YoY on a weak Q1 tender cycle, a seasonality/timing effect rather than demand loss. Management's own framing credits consolidated growth primarily to "the strong performance of the India business," with international operations "broadly stable."

₹
1,986.662,127.032,267.42,407.772,548.142,479.108-0308-2509-1710-1211-0411-05Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹2,479.1, up 13.5% over the past month of trading.

₹ Cr
036.1172.23108.3417.3Q1 FY26rev ₹84 Cr14.33Q2 FY26rev ₹71 Cr9.31Q3 FY26rev ₹77 Cr16.55Q4 FY26rev ₹100 Cr96.73Q1 FY27rev ₹77 Cr20.63Q2 FY27rev ₹98 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

What management guided (1 FY-2027 call)
No formal forward guidance. Management maintains long-term confidence in biologicals portfolio, international expansion, and R&D pipeline (Brucella recombinant, LPAI vaccine commercialization) but refuses specific FY27 revenue/margin targets. Africa tax-free status till 2030.

Management gave no formal FY27 revenue or margin guidance at the last concall and none accompanies this result either; that stance is unchanged. The headline QoQ swing — consolidated PAT down 79% from ₹96.73 Cr in Q1 FY27 — is not a deterioration: Q1's figure was inflated by an ₹85.77 Cr non-recurring gain after Hester Africa's loan with the Gates Foundation was amended (principal cut from USD 12 Mn to USD 5 Mn, accrued interest waived, remaining balance made interest-free), booked as an Ind AS 109 extinguishment gain. Stripped of that, Q2's underlying consolidated performance is a sequential improvement, not a decline. Alongside results, the board approved a fresh unsecured USD 1 Mn loan to Hester Africa (9% interest, 3-year tenure) and the company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd, concluding the partial exit begun with last year's 43.81% stake sale.

  • W1

    Whether consolidated EBITDA margin holds near 37% (vs 33% a year ago) once the one-off's residual effects fully roll off in Q3

  • W2

    Animal Healthcare division: Q2 grew 34% YoY on tender execution but H1 is still -14% YoY — watch if Q3 tender flow sustains the recovery

  • W3

    Utilisation of the new USD 1 Mn Hester Africa loan (agreement expected by 15 November 2026) against stated international expansion plans

Consolidated PBT (₹26.454 Cr) = totalIncome−totalExpenses (₹24.131 Cr) + JV profit share (₹1.904 Cr) + exceptional gain (₹0.419 Cr) — both sit below the 'total expenses' line by design. Year-ago quarter had no exceptional item, so YoY is clean; QoQ is distorted by Q1 FY27's ₹85.77 Cr one-time Gates Foundation loan-modification gain at Hester Africa.

Informational and educational content only. Not investment advice.